Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2019 3
2020 4
2021 8
2022 10
2023 9
2024 11
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Roadmap for Achieving Universal Antiretroviral Treatment.
Sokhela S, Lalla-Edward S, Siedner MJ, Majam M, Venter WDF. Sokhela S, et al. Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:99-117. doi: 10.1146/annurev-pharmtox-052020-094321. Annu Rev Pharmacol Toxicol. 2023. PMID: 36662580 Free PMC article. Review.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Among authors: sokhela s. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Venter WDF, et al. Among authors: sokhela s. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.
The long wait for long-acting HIV prevention and treatment formulations.
Venter WDF, Gandhi M, Sokhela S, Sikwese K, Bygrave H, Gama LD, Mphothulo N, Jamieson L, Siedner MJ, Pozniak AL, Rojo P, Baptiste SL, Wambui J, Meyer-Rath G, Honermann B, Warren M, Bekker LG, Sinxadi P, Collins S, Burry J, Möller K, Clayden P, Owen A, Hill A. Venter WDF, et al. Among authors: sokhela s. Lancet HIV. 2024 Oct;11(10):e711-e716. doi: 10.1016/S2352-3018(24)00173-5. Epub 2024 Aug 16. Lancet HIV. 2024. PMID: 39159655 Review.
Coronavirus Host Genomics Study: South Africa (COVIGen-SA).
May AK, Seymour H, Etheredge H, Maher H, Nunes MC, Madhi SA, Sokhela SM, Venter WDF, Martinson N, Nabeemeeah F, Cohen C, Moyes J, Walaza S, Tempia S, Kleynhans J, von Gottberg A, Nel J, Dawood H, Variava E, Tollman S, Kahn K, Herbst K, Wong EB, Tiemessen CT, van Blydenstein A, Murray L, Venter M, Fabian J, Ramsay M. May AK, et al. Among authors: sokhela sm. Glob Health Epidemiol Genom. 2022 Oct 6;2022:7405349. doi: 10.1155/2022/7405349. eCollection 2022. Glob Health Epidemiol Genom. 2022. PMID: 36263375 Free PMC article.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, Chandiwana N, Mashabane N, Tembo A, Simmons B, Lalla-Edward S, Siedner MJ, Sinxadi P, Hermans L, Fairlie L, Vos A, Abrams E, Manne-Goehler JM, Moorhouse M, Clayden P, Norris S, Qavi A, Chersich M, Masenya M, Arulappan N, Hill A. Sokhela S, et al. Open Forum Infect Dis. 2024 Jan 24;11(3):ofae007. doi: 10.1093/ofid/ofae007. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38529213 Free PMC article.
Two-drug regimens for the treatment of HIV in Africa.
Mambule I, Norcross C, Achieng Ombajo L, Sokhela S, Laker Odongpiny EA, Owarwo N, Lawrence DS, Ruzagira E, Cresswell FV. Mambule I, et al. Among authors: sokhela s. Lancet HIV. 2024 Jun;11(6):e419-e426. doi: 10.1016/S2352-3018(24)00061-4. Epub 2024 Apr 30. Lancet HIV. 2024. PMID: 38697180 Review.
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF. Manne-Goehler J, et al. Among authors: sokhela s. J Int AIDS Soc. 2024 Jul;27(7):e26268. doi: 10.1002/jia2.26268. J Int AIDS Soc. 2024. PMID: 38978403 Free PMC article. Clinical Trial.
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, Qavi A, Mirchandani M, Venter WDF. Bosch B, et al. Among authors: sokhela s. Clin Infect Dis. 2023 Apr 17;76(8):1492-1495. doi: 10.1093/cid/ciac949. Clin Infect Dis. 2023. PMID: 36519389 Clinical Trial.
45 results